Liquid biopsy diagnostic solution for non-invasive cancer monitoring and treatment personalization through cell-free DNA analysis. Automates plasma separation, DNA extraction, and quantitation to reduce pre-analytical variability and enable frequent patient monitoring for improved treatment response...
Manufactured by
Jyvaskyla, Finland
BiopSense is developing a fully automated blood processing solution to help health care professionals, such as laboratories to solve the current complicated biopsy workflows with our unique cartridge technology. With the number of treatment options constantly increasing, more frequent monitoring helps the oncologists to respond more quickly in case the treatment is not satisfactory, or a drug resistance is induced. As a result, the patient will receive efficient treatment faster. Cancer medications are often expensive and predicting the effect could be hard, but they can also have the potential to completely cure the cancer. That is why it is important to find the correct medication right as soon as possible. Therefore, screening and constant monitoring for cancer with liquid biopsy is an effective way to improve the quality of cancer treatments and to reduce the burden of cancer. We aim to replace invasive sampling with a less and non-invasive option – liquid biopsy sampling - fully automated.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
GENETRON HEALTH (BEIJING) CO., LTD
China · 2 relevant products
Eone-Diagnomics Genome Center
South Korea · 2 relevant products
Bio-Techne Diagnostics
United States · 2 relevant products
NOROVA
China · 4 relevant products
guangzhou biotron technolongy co.,ltd
China · 4 relevant products
GeneCker Co., Ltd.
South Korea · 2 relevant products
Novos Biotech (SZ) Limited
China · 2 relevant products
Rapid Viral Detection Systems
United States · 1 relevant product
Nonacus
United Kingdom · 4 relevant products
Glycanostics, s.r.o.
Slovakia · 2 relevant products
30 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →4 more sourcing countries available
Get free access to all sourcing countries identified for this product.
See all countries →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 66 closest product alternatives
GENETRON HEALTH (BEIJING) CO., LTD · China
Molecular diagnostic test utilizing circulating tumor DNA and biomarkers from blood samples. Enables non-invasive cancer screening and early detection. Supports monitoring of treatment response and recurrence in cancer patients.
Eone-Diagnomics Genome Center · South Korea
Blood-based diagnostic testing methodology for non-invasive detection of genetic abnormalities and disease markers. Uses advanced sequencing techniques to analyze circulating DNA and genetic material.
Bio-Techne Diagnostics · United States
Advanced molecular assays for liquid biopsy applications enabling non-invasive detection of circulating biomarkers. Integrated with automated analysis for scalable clinical implementation.
NOROVA · China
Precision diagnostic service utilizing liquid biopsy technology for early detection and monitoring of malignant tumors. Analyzes circulating biomarkers from patient blood samples. Enables non-invasive assessment of tumor characteristics and treatment response.
guangzhou biotron technolongy co.,ltd · China
Advanced liquid biopsy system for non-invasive detection and analysis of circulating tumor markers, circulating tumor cells, and cell-free DNA from blood samples.
GeneCker Co., Ltd. · South Korea
Integrated platform for cancer diagnosis utilizing liquid biopsy techniques with CRISPR/Cas9 technology. Includes complete workflow from sample collection through DNA sequencing to result analysis.
Novos Biotech (SZ) Limited · China
Microfluidic biochips designed for liquid biopsy applications, enabling non-invasive detection of circulating biomarkers for cancer and disease diagnostics. The chips integrate sample preparation, separation, and detection capabilities in a compact format, supporting rapid analysis with minimal sample volumes for clinical screening and monitoring.
Rapid Viral Detection Systems · United States
Point-of-care liquid biopsy platform for rapid cancer detection with 99% accuracy and high sensitivity. Delivers non-invasive screening results in minutes, enabling early diagnosis across multiple cancer types at a lower cost than conventional test kits.
Nonacus · United Kingdom
Clinically validated next-generation sequencing panels for detecting genomic alterations through non-invasive liquid biopsy sampling. Designed to identify single nucleotide variants, indels, and copy number variations with sensitivity down to 0.1% variant allele frequency for oncology and constitutional genetics applications.
NOROVA · China
A diagnostic service utilizing independently developed CTC (circulating tumor cells) and ctDNA (circulating tumor DNA) detection platforms with high sensitivity and specificity. Compared to traditional detection methods, it can identify more disease information to achieve individualized precision therapy for tumor patients. Liquid biopsy is minimally invasive and painless, providing comprehensive tumor-related information from a single blood sample, offering strong support for malignant tumor diagnosis and treatment as a complement to traditional tissue biopsy.
Novos Biotech (SZ) Limited · China
Microfluidic biochips specifically engineered for liquid biopsy applications, enabling detection and analysis of circulating biomarkers. These chips support early disease detection and monitoring through minimally invasive sampling.
Glycanostics, s.r.o. · Slovakia
Non-invasive liquid biopsy test for early-stage prostate cancer detection using glycan analysis in blood serum. Achieves up to 90% accuracy using magnetic particle-based technology with minimal blood sample requirement of 10 microliters.
54 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products